Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Chelsea Edgar"'
Autor:
Erica Stone, Kyle Carter, Ellen Wagner, Michael Asensio, Emily Benzie, Yao Chiang, Garry Coles, Chelsea Edgar, Bishal Gautam, Ashley Gras, Jackson Leong, Renee Leong, Vishal Manickam, Rena Mizrahi, Ariel Niedecken, Jasmeen Saini, Savreet Sandhu, Jan Fredrick Simons, Kacy Stadtmiller, Brendan Tinsley, LaRee Tracy, Nicholas Wayham, Yoong Wearn Lim, David Johnson, Adam Adler
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a0b2ca38ebb73246f08d1e5690870de
https://doi.org/10.1136/jitc-2022-sitc2022.1389
https://doi.org/10.1136/jitc-2022-sitc2022.1389
Autor:
Erica L Stone, Kyle P Carter, Ellen K Wagner, Michael A Asensio, Emily Benzie, Yao Yuan Chiang, Garry L Coles, Chelsea Edgar, Bishal K Gautam, Ashley Gras, Jackson Leong, Renee Leong, Vishal A Manickam, Rena A Mizrahi, Ariel R Niedecken, Jasmeen Saini, Savreet K Sandhu, Jan Fredrick Simons, Kacy Stadtmiller, Brendan Tinsley, LaRee Tracy, Nicholas P Wayham, Yoong Wearn Lim, Adam S Adler, David S Johnson
Publikováno v:
Cancer Immunology Research. 10:A32-A32
Anti-CTLA-4 antibodies such as ipilimumab were among the first immuno-oncology agents to show significantly improved outcomes for patients. However, existing anti-CTLA-4 therapies fail to induce a response in a majority of patients and can induce sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa01c69f115a5cbabbd7bbb2e0b1ad8b
https://doi.org/10.1158/2326-6074.tumimm22-a32
https://doi.org/10.1158/2326-6074.tumimm22-a32
Autor:
Kyle P Carter, Yao Y. Chiang, Vishal A. Manickam, Emily Benzie, Nicholas Wayham, David S. Johnson, Rena A. Mizrahi, Jasmeen Saini, Garry L. Coles, Savreet K. Sandhu, Eric A. Stone, Jan Fredrick Simons, Adam S. Adler, Ellen K. Wagner, Ashley Gras, Chelsea Edgar, LaRee Tracy, Brendan Tinsley, Jackson Leong, Kacy Stadtmiller, Ariel R Niedecken, Renee Leong, Yoong Wearn Lim, Bishal K. Gautam, Michael A. Asensio
Anti-CTLA-4 antibodies such as ipilimumab were among the first immune-oncology agents to show significantly improved outcomes for patients. However, existing anti-CTLA-4 therapies fail to induce a response in a majority of patients and can induce sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f6edafd41945bb756870a8746a1366a
https://doi.org/10.1101/2021.07.12.452090
https://doi.org/10.1101/2021.07.12.452090
